Nachrichten zur Nanoviricides Inc. Aktie

Market movers: Amer Sports, Tiziana Life Sciences, Ideal Power, NanoViricides...

…

NanoViricides closes $2M direct offering

NanoViricides (NYSE-A:NNVC) announced the closing of its previously disclosed registered direct offering, raising about $2 million in gross proceeds before...…

NanoViricides says its broad-spectrum antiviral could help tackle Ebola strain behind Congo outbreak

NanoViricides (NYSE-A:NNVC), the US clinical-stage drugmaker, has said its lead drug candidate NV-387 could be effective against the Bundibugyo strain…

NanoViricides to raise $2M in registered direct offering

NanoViricides (NYSE-A:NNVC) said it has entered into a securities purchase agreement with a single institutional investor for gross proceeds of...…

Small cap wrap: Gunnison Copper, Graphene Manufacturing Group, NanoViricides…

…

NanoViricides says Phase I antiviral drug could address gap exposed by hantavirus cruise ship outbreak

NanoViricides (NYSE-A:NNVC) is pointing to its lead drug candidate NV-387 as a potential solution to a critical gap in infectious…

NanoViricides antiviral drug NV-387 wins FDA Orphan Drug Designation for measles treatment

NanoViricides (NYSE-A:NNVC) said on Monday its broad-spectrum antiviral drug NV-387 has been granted Orphan Drug Designation (ODD) by the US Food…

NanoViricides says NV-387 could address measles outbreaks as cases rise globally

NanoViricides (NYSE-A:NNVC) said on Tuesday its antiviral drug candidate NV-387 could help address rising measles cases globally, citing recent outbreaks...…

NanoViricides seeks FDA’s rare pediatric disease designation for antiviral candidate NV-387

NanoViricides (NYSE-A:NNVC) CEO Dr. Anil Diwan talked with Proactive about the company’s recent FDA application for rare pediatric disease designation…

NanoViricides files for Rare Pediatric Disease Designation for Measles Drug

…

NanoViricides seeks rare pediatric disease status for measles drug NV-387

NanoViricides (NYSE-A:NNVC) said on Tuesday it has filed an application with the US Food and Drug Administration for Rare Pediatric…

Small caps wrap: Alvopetro Energy, NanoViricides, New Era Energy & Digital, Digi Power X…

…

Small cap wrap: Alvopetro Energy, NanoViricides, New Era Energy & Digital, Digi Power X…

…

NanoViricides to begin Phase II trial of MPox treatment in Congo

NanoViricides (NYSE-A:NNVC) said on Wednesday it expects to begin a Phase II clinical trial of its antiviral candidate NV-387 for…

Small cap wrap: NanoViricides, Millennial Potash, Gunnison Copper, Century Lithium…

…

NanoViricides CEO discusses progress of broad-spectrum antiviral candidate NV-387

NanoViricides (NYSE-A:NNVC) earlier this week provided an update on the advancement of its broad-spectrum antiviral candidate NV-387, outlining progress in...…

Small cap wrap: Aftermath Silver, M2i Global, NanoViricides, AtaiBeckley…

…

NanoViricides advances toward fully funded Phase II MPox trial in DRC

…

NanoViricides advances broad-spectrum antiviral NV-387 towards Phase II MPox study

NanoViricides has provided an update on the development of its investigational antiviral NV-387, alongside the filing of its quarterly report…

Small cap wrap: BioVie, VivoPower, NanoViricides, Aftermath Silver...

…

NanoViricides seeks FDA orphan status for MPox drug

NanoViricides (NYSE-A:NNVC), a clinical-stage biotechnology company developing broad-spectrum antiviral therapies, has filed for Orphan Drug Designation...…

Small cap wrap: Medicus Pharma, 1911 Gold, NanoViricides, Nextech3D.ai, NextSource Materials…

…

NanoViricides seeks orphan drug status with US FDA for measles treatment

NanoViricides (NYSE-A:NNVC), a clinical-stage biotechnology company developing broad-spectrum antivirals, said on Tuesday it has filed an application with...…

NanoViricides highlights need for broad-spectrum antivirals amid severe flu season

NanoViricides (NYSE-A:NNVC), a clinical-stage company developing broad-spectrum antiviral drugs, has highlighted the current influenza season as an example...…

Small cap wrap: Tiziana Life Sciences, NanoViricides, 1911 Gold, Protalix BioTherapeutics…

…

NanoViricides advances Phase 2 trials for broad-spectrum antiviral NV-378 in $17B market: analysts

NanoViricides (NYSE-A:NNVC) is gearing up to tackle multiple viral threats with Phase 2 trials for its broad-spectrum antiviral NV-378, as…

NanoViricides inks regulatory services deal to advance orphan drug strategy for antiviral NV-387

NanoViricides (NYSE-A:NNVC) said on Monday it signed a master services agreement with regulatory consulting firm Only Orphans Cote LLC to…

Market movers: Alphabet, Millennial Potash, NanoViricides...

…

NanoViricides raises cash, moves broad-spectrum antiviral NV-387 into Phase II trials

NanoViricides (NYSE-A:NNVC) is advancing its broad-spectrum antiviral NV-387, backed by new financing that strengthens its balance sheet and supports...…

Small cap wrap: American Resources, NanoViricides, AtaiBeckley…

…

NanoViricides raises $6M in direct offering with institutional investor

NanoViricides (NYSE-A:NNVC) said on Tuesday it has entered into a securities purchase agreement with a single healthcare institutional investor to raise...…

Small cap wrap: Millennial Potash, EnWave, NanoViricides, HIVE Digital Technologies…

…

NanoViricides receives approval to start Phase II clinical trial of NV-387 for MPox treatment in DRC

NanoViricides (NYSE-A:NNVC) announced that it has received approval to begin its Phase II Clinical Trial of NV-387 for the Treatment of MPox by the...…

Tesla, Take-Two Interactive, Airbnb, Alvopetro, NanoViricides: What brokers said this week

…

NanoViricides’ NV-387 shows broad antiviral potential, says Zacks

Analysts at Zacks have issued a new report on clinical stage biotech NanoViricides (NYSE-A:NNVC), saying that its lead drug candiate…

NanoViricides targets broad-spectrum virus threats

NanoViricides (NYSE-A:NNVC) CEO Dr Anil Diwan talked with Proactive about the company’s latest progress with its broad-spectrum antiviral candidate, NV-387....…

NanoViricides’ NV-387 shows potent anti-measles activity, highlighting broad-spectrum potential

…

Small cap wrap: Nevis Brands, Sonoro Gold, NanoViricides, Medicus Pharma…

…

NanoViricides reports antiviral activity of NV-387 against measles in preclinical studies

NanoViricides (NYSE-A:NNVC) said on Wednesday its experimental drug NV-387 showed strong activity against the measles virus in both cell culture…

Small cap wrap: NanoViricides, Century Lithium, Standard Uranium, Charbone Hydrogen…

…

NanoViricides says antiviral candidate NV-387 could address global measles surge

NanoViricides (NYSE-A:NNVC) said on Wednesday that its antiviral candidate NV-387 could play a key role in addressing the growing number of…

NanoViricides eyes revenue opportunities with broad-spectrum antiviral NV-387

NanoViricides (NYSE-A:NNVC) said on Wednesday that its broad-spectrum antiviral candidate NV-387 has shown strong preclinical efficacy against multiple...…

NanoViricides says lead antiviral boosted survival in measles-infected mice

NanoViricides (NYSE-A:NNVC) said on Monday that its broad-spectrum antiviral candidate, NV-387, showed strong effectiveness in preclinical studies using a...…

NanoViricides says MPox drug candidate NV-387 poised for Phase II trial as WHO extends global health emergency

NanoViricides (NYSE-A:NNVC) is preparing for Phase II clinical testing in Africa, following the World Health Organization’s recent extension of the…

NanoViricides positioned at forefront of Mpox treatment efforts, says Zacks

NanoViricides (NYSE-A:NNVC) is preparing to launch a Phase 2 clinical trial of its lead antiviral candidate NV-387 for the treatment…

Market movers: Autodesk, Waters, NanoViricides...

…

NanoViricides nears completion of clinical trial design for MPox treatment

NanoViricides (NYSE-A:NNVC) said on Monday it is close to finalizing the design of a Phase II adaptive clinical trial for…

NanoViricides advances antiviral candidate NV-387 into Phase 2 trials for Mpox

NanoViricides (NYSE-A:NNVC) announced it is moving forward with Phase 2 clinical development of its experimental antiviral therapy, NV-387, for the...…

Small cap wrap: Fineqia, NanoViricides, Standard Uranium...

…

NanoViricides touts antiviral NV-387 as tool against new COVID variant

NanoViricides (NYSE-A:NNVC) said its experimental antiviral drug NV-387 could play a role in combating emerging threats from COVID-19 and bird…